Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
J Neurol
    April 2024
  1. ROSENSTEIN I, Nordin A, Sabir H, Malmestrom C, et al
    Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
    J Neurol. 2024 Apr 26. doi: 10.1007/s00415-024-12389.
    >> Share

  2. FONTE J, Stabile A, de Curtis M, Di Giacomo R, et al
    Seizures in autoimmune-associated epilepsy: a long-term video-EEG monitoring study.
    J Neurol. 2024 Apr 24. doi: 10.1007/s00415-024-12385.
    >> Share

  3. NAUTA IM, van Dam M, Bertens D, Kessels RPC, et al
    Improved quality of life and psychological symptoms following mindfulness and cognitive rehabilitation in multiple sclerosis and their mediating role for cognition: a randomized controlled trial.
    J Neurol. 2024 Apr 23. doi: 10.1007/s00415-024-12327.
    >> Share

  4. SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
    Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
    J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
    >> Share

  5. HIRT J, Dembowska K, Woelfle T, Axfors C, et al
    Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
    J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
    >> Share

  6. SINGER BA, Feng J, Chiong-Rivero H
    Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
    J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
    >> Share

  7. ZHANG Y, Liu D, Zhang Z, Huang X, et al
    Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
    J Neurol. 2024 Apr 11. doi: 10.1007/s00415-024-12367.
    >> Share

  8. STALTER J, Pars K, Witt K
    Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
    J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
    >> Share

  9. MARTINEZ-MARTINEZ L, Lacruz AC, Querol L, Cortes-Vicente E, et al
    Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12317.
    >> Share

  10. CELIK M, Baba C, Irmak C, Ozakbas S, et al
    Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
    >> Share

  11. STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
    Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
    >> Share

  12. TERAYAMA A, Kuwahara M, Yoshikawa K, Yamagishi Y, et al
    Takotsubo cardiomyopathy in Guillain-Barre syndrome.
    J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12295.
    >> Share

  13. MAIDA E, Moccia M, Palladino R, Borriello G, et al
    ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
    J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
    >> Share

  14. SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
    Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
    J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
    >> Share

  15. GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
    Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
    J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
    >> Share

  16. MCWILLIAM O, Gramkow MH, Blaabjerg M, Clemmensen FK, et al
    Differentiating anti-IgLON5 disease and Lewy body dementia: a systematic review.
    J Neurol. 2024;271:1707-1716.
    >> Share

  17. WANG Y, Hu C, Aljarallah S, Reyes Mantilla M, et al
    Expanding clinical profiles and prognostic markers in stiff person syndrome spectrum disorders.
    J Neurol. 2024;271:1861-1872.
    >> Share

  18. TEDONE N, Vizzino C, Meani A, Gallo A, et al
    The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
    J Neurol. 2024;271:1813-1823.
    >> Share

  19. GLASER A, Butzkueven H, van der Walt A, Gray O, et al
    Big Multiple Sclerosis Data network: an international registry research network.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
    >> Share

  20. HUA T, Fan H, Duan Y, Tian D, et al
    Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
    >> Share

    March 2024
  21. GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
    Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
    J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
    >> Share

  22. SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
    Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
    >> Share

  23. MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
    Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
    J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
    >> Share

  24. ZHANG H, Ma J, Feng Y, Ma H, et al
    Efgartigimod in the treatment of Guillain-Barre syndrome.
    J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12321.
    >> Share

  25. FUCHS L, Shelly S, Vigiser I, Kolb H, et al
    Real-World experience with efgartigimod in patients with myasthenia gravis.
    J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12293.
    >> Share

  26. PILOTTO S, Floris M, Solla P, Pugliatti M, et al
    Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
    J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
    >> Share

  27. LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
    Correction to: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
    J Neurol. 2024 Mar 23. doi: 10.1007/s00415-024-12238.
    >> Share

  28. GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
    Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
    J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
    >> Share

  29. ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
    Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
    J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
    >> Share

  30. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
    J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
    >> Share

  31. VILASECA A, Farina A, Villagran-Garcia M, Pegat A, et al
    Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
    J Neurol. 2024 Mar 11. doi: 10.1007/s00415-024-12252.
    >> Share

  32. KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
    The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
    >> Share

  33. HEGEN H, Berek K, Deisenhammer F, Berger T, et al
    Sex impacts treatment decisions in multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
    >> Share

  34. HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
    Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
    >> Share

  35. ZID Y, Robertson NP
    Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
    J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
    >> Share

  36. LI J, Wu X, Chu T, Tan X, et al
    The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
    J Neurol. 2024 Mar 3. doi: 10.1007/s00415-024-12247.
    >> Share

  37. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
    >> Share

    February 2024
  38. SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
    Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
    J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
    >> Share

  39. TOLJAN K, Briggs FBS
    Male sexual and reproductive health in multiple sclerosis: a scoping review.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
    >> Share

  40. LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
    A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
    >> Share

  41. VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
    Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
    J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
    >> Share

  42. NGUYEN TT, Chae J, Kang JJ, Oh SY, et al
    Saccadic fatigue as an early indicator for diagnosing myasthenia gravis.
    J Neurol. 2024 Feb 25. doi: 10.1007/s00415-024-12262.
    >> Share

  43. WEISS MD, Freimer M, Leite MI, Maniaol A, et al
    Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
    J Neurol. 2024 Feb 24. doi: 10.1007/s00415-024-12209.
    >> Share

  44. OHNARI K, Hashimoto T, Iwanaka Y, Ohnari K, et al
    Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.
    J Neurol. 2024 Feb 23. doi: 10.1007/s00415-024-12245.
    >> Share

  45. GREGULETZ P, Plotz M, Baade-Buttner C, Bien CG, et al
    Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12224.
    >> Share

  46. CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
    Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
    >> Share

  47. BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
    The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
    J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
    >> Share

  48. HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
    Prodromal multiple sclerosis: considerations and future utility.
    J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
    >> Share

  49. VANCURA J, Boyd NK, Vogel BN, Nagesh D, et al
    Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutieres syndrome.
    J Neurol. 2024;271:1019-1022.
    >> Share

    January 2024
  50. BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
    Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
    >> Share

  51. BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
    Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
    >> Share

  52. NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
    Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
    J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
    >> Share

  53. CENSI S, Bisaccia G, Gallina S, Tomassini V, et al
    Guillain-Barre syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
    J Neurol. 2024 Jan 17. doi: 10.1007/s00415-024-12186.
    >> Share

  54. FENG G, Posa S, Sureshkumar A, Simpson S, et al
    Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
    J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
    >> Share

  55. ZHENG P, Sandroff BM, Motl RW
    Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
    J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
    >> Share

  56. MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
    Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
    J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
    >> Share

  57. TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
    Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
    J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
    >> Share

  58. LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
    Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
    J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
    >> Share

  59. FAVRUZZO F, Palmieri A, Giopato F, Cardellini D, et al
    Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and Varicella-Zoster virus infections: a case report.
    J Neurol. 2024;271:75-78.
    >> Share

  60. NEUMANN B, Angstwurm K, Dohmen C, Mergenthaler P, et al
    Weaning and extubation failure in myasthenic crisis: a multicenter analysis.
    J Neurol. 2024;271:564-574.
    >> Share

  61. WIESENFARTH M, Stamminger T, Zizer E, Tumani H, et al
    Neurological manifestation of HEV infection: still a rare disease entity?
    J Neurol. 2024;271:386-394.
    >> Share

  62. MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
    Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
    J Neurol. 2024;271:374-385.
    >> Share

  63. KUMPFEL T, Giglhuber K, Aktas O, Ayzenberg I, et al
    Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
    J Neurol. 2024;271:141-176.
    >> Share

    December 2023
  64. AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
    Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
    J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
    >> Share

  65. LIU M, Ren H, Wang L, Fan S, et al
    Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.
    J Neurol. 2023 Dec 23. doi: 10.1007/s00415-023-12128.
    >> Share

  66. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
    >> Share

  67. ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
    Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
    >> Share

  68. MISTRI D, Valsasina P, Storelli L, Filippi M, et al
    Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
    J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
    >> Share

  69. HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
    Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
    J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
    >> Share

  70. COVEY TJ, Golan D, Sergott R, Wilken J, et al
    Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
    J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
    >> Share

  71. ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
    Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
    >> Share

  72. TSAI CC, Jette S, Tremlett H
    Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
    J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
    >> Share

  73. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
    J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
    >> Share

    November 2023
  74. MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
    Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
    J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
    >> Share

  75. MISTRI D, Tedone N, Biondi D, Vizzino C, et al
    Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
    J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
    >> Share

  76. JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
    Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
    >> Share

  77. BISECCO A, Matrone F, Capobianco M, De Luca G, et al
    COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
    >> Share

  78. SUN Y, Li G, Liu X, Zhao X, et al
    Cerebral glucose hypometabolism and hypoperfusion of cingulate gyrus: an imaging biomarker of autoimmune encephalitis with psychiatric symptoms.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12051.
    >> Share

  79. KENNEDY PGE, George W, Yu X
    The elusive nature of the oligoclonal bands in multiple sclerosis.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
    >> Share

  80. DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
    SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
    J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
    >> Share

  81. FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
    Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
    J Neurol. 2023;270:5392-5397.
    >> Share

  82. JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
    Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
    J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
    >> Share

    October 2023
  83. MANTERO V, Cordano C, Balgera R, Basilico P, et al
    Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
    >> Share

  84. KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
    Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
    >> Share

  85. DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
    Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
    >> Share

  86. RIVEL M, Achiron A, Stern Y, Zeilig G, et al
    Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
    J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
    >> Share

  87. ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
    Identification and management of subclinical disease activity in early multiple sclerosis: a review.
    J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
    >> Share

  88. ZINGANELL A, Gobel G, Berek K, Hofer B, et al
    Multiple sclerosis in the elderly: a retrospective cohort study.
    J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
    >> Share

  89. SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
    Multiple sclerosis: time for early treatment with high-efficacy drugs.
    J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
    >> Share

  90. RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
    Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
    >> Share

  91. MANZANO GS, McEntire C, Venna N
    Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-11992.
    >> Share

  92. ZHANG Z, Wang Z, Du X, Huang X, et al
    Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
    J Neurol. 2023 Oct 7. doi: 10.1007/s00415-023-12036.
    >> Share

  93. KRAKER JA, Chen JJ
    An update on optic neuritis.
    J Neurol. 2023;270:5113-5126.
    >> Share

  94. BRISCA G, Marini C, Buratti S, Mariani M, et al
    Acute pediatric encephalitis: etiology, course, and outcome of a 12-year single-center immunocompetent cohort.
    J Neurol. 2023;270:5034-5047.
    >> Share

  95. WANG R, Sun D, Du Q, Shi Z, et al
    Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
    J Neurol. 2023;270:5085-5089.
    >> Share

    September 2023
  96. RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
    Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
    >> Share

  97. LI Y, Saul A, Taylor B, Ponsonby AL, et al
    Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
    J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
    >> Share

  98. KERNER C, Kotobelli K, Appleby BS, Cohen ML, et al
    Pathological findings in autoimmune encephalitis autopsy specimens from cases of suspected prion disease.
    J Neurol. 2023 Sep 27. doi: 10.1007/s00415-023-12003.
    >> Share

  99. WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
    Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
    >> Share

  100. FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
    Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
    J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
    >> Share

  101. GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
    Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.
    J Neurol. 2023 Sep 14. doi: 10.1007/s00415-023-11967.
    >> Share

  102. MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
    Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
    J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
    >> Share

  103. DI STEFANO V, Alonge P, Rini N, Militello M, et al
    Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
    J Neurol. 2023 Sep 8. doi: 10.1007/s00415-023-11970.
    >> Share

  104. JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
    Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
    J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
    >> Share

  105. MCCOMBE JA, Klassen BT, Flanagan EP, Teener JW, et al
    Eculizumab for the treatment of glycine receptor antibody associated stiff-person syndrome.
    J Neurol. 2023;270:4555-4557.
    >> Share

  106. NAKAMURA N, Ishikawa H, Matsuyama H, Shindo A, et al
    Neuromyelitis optica spectrum disorder with a familial Mediterranean fever gene E84K mutation.
    J Neurol. 2023;270:4529-4532.
    >> Share

    August 2023
  107. FERRAND M, Epstein J, Soudant M, Guillemin F, et al
    Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis.
    J Neurol. 2023 Aug 31. doi: 10.1007/s00415-023-11905.
    >> Share

  108. BONACCHI R, Valsasina P, Pagani E, Meani A, et al
    Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11948.
    >> Share

  109. TOSCANO S, Chisari CG, Lo Fermo S, Gulino G, et al
    A dynamic interpretation of kappaFLC index for the diagnosis of multiple sclerosis: a change of perspective.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11952.
    >> Share

  110. JAKIMOVSKI D, Zivadinov R, Weinstock Z, Fuchs TA, et al
    Cortical thickness and cognition in older people with multiple sclerosis.
    J Neurol. 2023 Aug 27. doi: 10.1007/s00415-023-11945.
    >> Share

  111. KUDO A, Yaguchi H, Tanaka K, Kimura A, et al
    A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution.
    J Neurol. 2023 Aug 23. doi: 10.1007/s00415-023-11946.
    >> Share

  112. GOERTZEN A, Altawashi AK, Rieck J, Veh RW, et al
    Autoimmune processes in neurological patients are much more common than presently suspected.
    J Neurol. 2023 Aug 21. doi: 10.1007/s00415-023-11901.
    >> Share

  113. CHANSON JB, Bouhour F, Aube-Nathier AC, Mallaret M, et al
    Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study.
    J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11925.
    >> Share

  114. SPIERER R, Lavi I, Bloch S, Mazar M, et al
    Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
    J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11935.
    >> Share

  115. KLETENIK I, Cohen AL, Glanz BI, Ferguson MA, et al
    Multiple sclerosis lesions that impair memory map to a connected memory circuit.
    J Neurol. 2023 Aug 2. doi: 10.1007/s00415-023-11907.
    >> Share

  116. AL-ANI A, Chen JJ, Costello F
    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges.
    J Neurol. 2023;270:4132-4150.
    >> Share

    July 2023
  117. MAHMOOD A, Hawken J, Robertson NP
    Clinical trials in myasthenia gravis.
    J Neurol. 2023 Jul 31. doi: 10.1007/s00415-023-11903.
    >> Share

  118. QIN M, Chen J, Guo X, Xiang X, et al
    Movement disorders in autoimmune encephalitis: an update.
    J Neurol. 2023 Jul 31. doi: 10.1007/s00415-023-11881.
    >> Share

  119. ROEBEN B, Scharf M, Miske R, Teegen B, et al
    Seroprevalence of autoimmune antibodies in degenerative ataxias: a broad, disease-controlled screening in 456 subjects.
    J Neurol. 2023 Jul 28. doi: 10.1007/s00415-023-11900.
    >> Share

  120. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
    Correction to: Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
    J Neurol. 2023 Jul 26. doi: 10.1007/s00415-023-11874.
    >> Share

  121. NOTEBOOM S, van Nederpelt DR, Bajrami A, Moraal B, et al
    Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.
    J Neurol. 2023 Jul 19. doi: 10.1007/s00415-023-11870.
    >> Share

  122. ROCCA MA, Valsasina P, Lamanna MT, Colombo B, et al
    Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
    J Neurol. 2023 Jul 18. doi: 10.1007/s00415-023-11858.
    >> Share

  123. LOMBARDO-DEL TORO P, Bragado-Trigo I, Arroyo P, Tena-Cucala R, et al
    Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim.
    J Neurol. 2023 Jul 17. doi: 10.1007/s00415-023-11865.
    >> Share

  124. PETROU P, Achiron A, Cohen EG, Garty M, et al
    Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint.
    J Neurol. 2023 Jul 12. doi: 10.1007/s00415-023-11846.
    >> Share

  125. AMATO MP, Bergamaschi R, Centonze D, Mirabella M, et al
    Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
    J Neurol. 2023 Jul 5. doi: 10.1007/s00415-023-11820.
    >> Share

  126. NICULAE AS, Niculae LE, Vacaras C, Vacaras V, et al
    Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2023 Jul 2. doi: 10.1007/s00415-023-11841.
    >> Share

  127. MOOG TM, Smith AD, Burgess KW, McCreary M, et al
    High-efficacy therapies reduce clinical and radiological events more effectively than traditional treatments in neuromyelitis optica spectrum disorder.
    J Neurol. 2023;270:3595-3602.
    >> Share

  128. JARIUS S, Aktas O, Ayzenberg I, Bellmann-Strobl J, et al
    Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    J Neurol. 2023;270:3341-3368.
    >> Share

  129. LUMSDEN DE, Lim M, Irani S
    Letter to the editors: comment on "Status dystonicus in adult patients with anti-N-methyl-D-asparate-acid receptor encephalitis".
    J Neurol. 2023;270:3630-3631.
    >> Share

  130. TEZUKA T, Okuzumi S, Nakashima C, Ide T, et al
    Dysautonomia associated with immune checkpoint inhibitors.
    J Neurol. 2023;270:3413-3423.
    >> Share

    June 2023
  131. RUGGIERI S, Prosperini L, Petracca M, Logoteta A, et al
    The added value of spinal cord lesions to disability accrual in multiple sclerosis.
    J Neurol. 2023 Jun 29. doi: 10.1007/s00415-023-11829.
    >> Share

  132. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
    Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
    J Neurol. 2023 Jun 21. doi: 10.1007/s00415-023-11806.
    >> Share

  133. LIANG Y, Wang G, Li B, Li G, et al
    Autoimmune glial fibrillary acidic protein astrocytosis mimicking tuberculous meningitis: a retrospective study.
    J Neurol. 2023 Jun 20. doi: 10.1007/s00415-023-11818.
    >> Share

  134. ROSENSTEIN I, Axelsson M, Novakova L, Malmestrom C, et al
    Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Jun 14. doi: 10.1007/s00415-023-11817.
    >> Share

  135. KRIEF N, Gabriel R, Cauquil C, Adams D, et al
    Clinical features and maternal and fetal outcomes in women with Guillain-Barre syndrome in pregnancy.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11808.
    >> Share

  136. GRANGE E, Solaro C, Di Giovanni R, Marengo D, et al
    The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11801.
    >> Share

  137. CHOMPOOPONG P, Rezk M, Mirman I, Berini SE, et al
    TS-HDS autoantibody: clinical characterization and utility from real-world tertiary care center experience.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11798.
    >> Share

  138. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Jun 5. doi: 10.1007/s00415-023-11784.
    >> Share

  139. HTET ZM, Tallantyre E
    Optic neuritis and MOGAD.
    J Neurol. 2023;270:3278-3279.
    >> Share

  140. HOLTZER R, Choi J, Motl RW, Foley FW, et al
    Individual reserve in aging and neurological disease.
    J Neurol. 2023;270:3179-3191.
    >> Share

  141. YIN Z, Qiu Y, Duan A, Fang T, et al
    Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    J Neurol. 2023;270:2950-2963.
    >> Share

  142. ROSSI S, Gelsomino F, Rinaldi R, Muccioli L, et al
    Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    J Neurol. 2023;270:2975-2986.
    >> Share

    May 2023
  143. LOUAPRE C, Rosenzwajg M, Golse M, Roux A, et al
    A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 May 28. doi: 10.1007/s00415-023-11690.
    >> Share

  144. AZZIMONTI M, Preziosa P, Pagani E, Valsasina P, et al
    Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study.
    J Neurol. 2023 May 18. doi: 10.1007/s00415-023-11778.
    >> Share

  145. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11772.
    >> Share

  146. LIU B, Hu J, Sun C, Qiao K, et al
    Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study.
    J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11759.
    >> Share

  147. MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
    Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
    J Neurol. 2023;270:2559-2566.
    >> Share

  148. ZHANG Y, Cui L, Chen W, Huang H, et al
    Status dystonicus in adult patients with anti-N-methyl-D-aspartate-acid receptor encephalitis.
    J Neurol. 2023;270:2693-2701.
    >> Share

  149. DENG Z, Wang H, Huang K, Li Y, et al
    Association between vascular risk factors and idiopathic normal pressure hydrocephalus: a Mendelian randomization study.
    J Neurol. 2023;270:2724-2733.
    >> Share

    April 2023
  150. VARLEY JA, Strippel C, Handel A, Irani SR, et al
    Autoimmune encephalitis: recent clinical and biological advances.
    J Neurol. 2023 Apr 28. doi: 10.1007/s00415-023-11685.
    >> Share

  151. VOGRIG A, Versace S, Gigli GL, Fabris M, et al
    Eating reflex epilepsy of presumed autoimmune etiology after SARS-CoV-2 vaccination.
    J Neurol. 2023 Apr 28:1-5. doi: 10.1007/s00415-023-11723.
    >> Share

  152. KREMMYDA O, Feil K, Bardins S, Strupp M, et al
    Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11730.
    >> Share

  153. MEISEL A, Annane D, Vu T, Mantegazza R, et al
    Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11699.
    >> Share

  154. VAN DAM M, de Jong BA, Willemse EAJ, Nauta IM, et al
    A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11676.
    >> Share

  155. GILHUS NE
    Myasthenia gravis, respiratory function, and respiratory tract disease.
    J Neurol. 2023 Apr 26:1-12. doi: 10.1007/s00415-023-11733.
    >> Share

  156. MARGONI M, Pagani E, Preziosa P, Gueye M, et al
    Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
    J Neurol. 2023 Apr 24. doi: 10.1007/s00415-023-11736.
    >> Share

  157. KOUTSOURAKI E, Theodoros K, Eleni G, Marianna K, et al
    Autonomic nervous system disorders in multiple sclerosis.
    J Neurol. 2023 Apr 21. doi: 10.1007/s00415-023-11725.
    >> Share

  158. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Apr 19. doi: 10.1007/s00415-023-11686.
    >> Share

  159. GANAPATHY SUBRAMANIAN R, Zivadinov R, Bergsland N, Dwyer MG, et al
    Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis.
    J Neurol. 2023 Apr 17. doi: 10.1007/s00415-023-11709.
    >> Share

  160. GADOTH A, Devine MF, Pittock SJ, McKeon A, et al
    Sleep disturbances associated with DPPX autoantibodies: a case series.
    J Neurol. 2023 Apr 7. doi: 10.1007/s00415-023-11698.
    >> Share

  161. YEO T, Siew RWE, Gulam MY, Tye JSN, et al
    COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
    J Neurol. 2023 Apr 7:1-9. doi: 10.1007/s00415-023-11692.
    >> Share

  162. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 Apr 7:1-12. doi: 10.1007/s00415-023-11700.
    >> Share

  163. VRENKEN H, Battaglini M, de Vos ML, Nagtegaal GJ, et al
    Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon beta-1a.
    J Neurol. 2023;270:2271-2282.
    >> Share

  164. LEHTO J, Sucksdorff M, Nylund M, Raitanen R, et al
    PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
    J Neurol. 2023;270:2329-2332.
    >> Share

  165. GHOLIZADEH S, Exuzides A, Lewis KE, Palmer C, et al
    Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort.
    J Neurol. 2023;270:2048-2058.
    >> Share

  166. ASTBURY L, Kalra S, Tanasescu R, Constantinescu CS, et al
    CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
    J Neurol. 2023;270:2042-2047.
    >> Share

  167. HIEKE A, Spenner M, Schmitz F, Schumacher A, et al
    The impact of the SARS-CoV-2-pandemic on patients with chronic inflammatory neuropathies: results from the German INHIBIT register.
    J Neurol. 2023;270:1815-1822.
    >> Share

  168. NEHME A, Lanthier S, Boulanger M, Aouba A, et al
    Diagnosis and management of adult primary angiitis of the central nervous system: an international survey on current practices.
    J Neurol. 2023;270:1989-1998.
    >> Share

    March 2023
  169. PLESS S, Woelfle T, Naegelin Y, Lorscheider J, et al
    Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
    J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11671.
    >> Share

  170. TORRES P, Sancho-Saldana A, Gil Sanchez A, Peralta S, et al
    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    J Neurol. 2023 Mar 18:1-12. doi: 10.1007/s00415-023-11575.
    >> Share

  171. ROMANO F, Motl RW, Valsasina P, Amato MP, et al
    Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis.
    J Neurol. 2023 Mar 18. doi: 10.1007/s00415-023-11664.
    >> Share

  172. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
    Correction to: Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
    J Neurol. 2023 Mar 13. doi: 10.1007/s00415-023-11646.
    >> Share

  173. MOGAVERO MP, Lanza G, Bruni O, DelRosso LM, et al
    Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis.
    J Neurol. 2023 Mar 11. doi: 10.1007/s00415-023-11655.
    >> Share

  174. VU T, Ortiz S, Katsuno M, Annane D, et al
    Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
    J Neurol. 2023 Mar 9. doi: 10.1007/s00415-023-11617.
    >> Share

  175. VELDKAMP R, D'hooge M, Sandroff BM, DeLuca J, et al
    Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study.
    J Neurol. 2023 Mar 7. doi: 10.1007/s00415-023-11636.
    >> Share

  176. LI G, You Q, Hou X, Zhang S, et al
    The effect of exercise on cognitive function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11649.
    >> Share

  177. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11644.
    >> Share

  178. BARLETTA VT, Herranz E, Treaba CA, Mehndiratta A, et al
    In vivo characterization of microglia and myelin relation in multiple sclerosis by combined (11)C-PBR28 PET and synthetic MRI.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11621.
    >> Share

  179. TAKAI K, Endo T, Seki T, Inoue T, et al
    Congestive myelopathy due to craniocervical junction arteriovenous fistulas mimicking transverse myelitis: a multicenter study on 27 cases.
    J Neurol. 2023;270:1745-1753.
    >> Share

  180. VABANESI M, Pinto AL, Vogrig A, Goncalves D, et al
    SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques.
    J Neurol. 2023;270:1691-1701.
    >> Share

  181. DIETMANN AS, Kruse N, Stork L, Gloth M, et al
    Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    J Neurol. 2023;270:1416-1429.
    >> Share

  182. NGUYEN TT, Kang JJ, Chae JH, Lee E, et al
    Oculomotor fatigability with decrements of saccade and smooth pursuit for diagnosis of myasthenia gravis.
    J Neurol. 2023 Mar 1. doi: 10.1007/s00415-023-11611.
    >> Share

  183. SCHEGK E, Beiser I, Achtnichts L, Nedeltchev K, et al
    Untreated anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia progressing over 27 years.
    J Neurol. 2023 Mar 1. doi: 10.1007/s00415-023-11632.
    >> Share

    February 2023
  184. BAETGE SJ, Filser M, Renner A, Raithel LM, et al
    Supporting brain health in multiple sclerosis: exploring the potential of neuroeducation combined with practical mindfulness exercises in the management of neuropsychological symptoms.
    J Neurol. 2023 Feb 25:1-14. doi: 10.1007/s00415-023-11616.
    >> Share

  185. MONTINI F, Nozzolillo A, Rancoita PMV, Zanetta C, et al
    Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.
    J Neurol. 2023 Feb 16:1-8. doi: 10.1007/s00415-023-11618.
    >> Share

  186. DIXON L, Colquhoun M, Taylor E, Carlucci F, et al
    Orbital giant cell arteritis: two cases of bilateral orbital inflammation and arterial diffusion restriction on MRI.
    J Neurol. 2023 Feb 11. doi: 10.1007/s00415-023-11593.
    >> Share

  187. SWINNEN S, De Wit D, Van Cleemput L, Cassiman C, et al
    Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review.
    J Neurol. 2023;270:1178-1186.
    >> Share

  188. HUANG L, Wang Y, Zhang R
    Retina thickness in clinically affected and unaffected eyes in patients with aquaporin-4 immunoglobulin G antibody seropositive neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
    J Neurol. 2023;270:759-768.
    >> Share

  189. FIONDA L, Lauletta A, Leonardi L, Perez JA, et al
    Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies.
    J Neurol. 2023;270:960-974.
    >> Share

  190. GERNERT JA, Wicklein R, Hemmer B, Kumpfel T, et al
    Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).
    J Neurol. 2023;270:1135-1140.
    >> Share

  191. MAGRO G, Barone S, Tosto F, De Martino A, et al
    Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.
    J Neurol. 2023;270:595-600.
    >> Share

    January 2023
  192. MINAMINO M, Miyamoto K, Kuwahara M, Yoshikawa K, et al
    Characteristics of Guillain-Barre syndrome in super-elderly individuals.
    J Neurol. 2023 Jan 16. doi: 10.1007/s00415-023-11567.
    >> Share

  193. CAGOL A, Fuertes NC, Stoessel M, Barakovic M, et al
    Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.
    J Neurol. 2023 Jan 10. doi: 10.1007/s00415-022-11535.
    >> Share

  194. SACCA F, Barnett C, Vu T, Peric S, et al
    Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
    J Neurol. 2023 Jan 4. doi: 10.1007/s00415-022-11517.
    >> Share

  195. LEE SU, Baek SH, Kim HJ, Choi JY, et al
    Acute comitant strabismus in anti-GQ1b antibody syndrome.
    J Neurol. 2023;270:486-492.
    >> Share

  196. HAGEBOUTROS K, Hattiangadi Thomas N, Hutchinson M, Banwell B, et al
    Neuropsychological functioning in children and adolescents with anti-NMDA receptor encephalitis (anti-NMDARE).
    J Neurol. 2023;270:402-412.
    >> Share

  197. YANG S, Zhang C, Zhang TX, Feng B, et al
    A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder.
    J Neurol. 2023;270:348-356.
    >> Share

  198. DAVION JB, Jougleux C, Lopes R, Leclerc X, et al
    Relation between retina, cognition and brain volumes in MS: a consequence of asymptomatic optic nerve lesions.
    J Neurol. 2023;270:240-249.
    >> Share

    December 2022
  199. BARBAGALLO M, Straumann D, Binaghi E, Schmick A, et al
    A rare case of a wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with cutaneous lupus erythematosus after COVID-19 infection.
    J Neurol. 2022 Dec 28:1-5. doi: 10.1007/s00415-022-11548.
    >> Share

  200. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
    Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
    J Neurol. 2022 Dec 27. doi: 10.1007/s00415-022-11540.
    >> Share

  201. TIERNEY P, Zekeridou A, Adam O
    Phosphodiesterase 10A autoimmunity presenting as cerebellar ataxia responsive to plasma exchange: a case report.
    J Neurol. 2022 Dec 26. doi: 10.1007/s00415-022-11542.
    >> Share

  202. LOONSTRA FC, Falize KF, de Ruiter LRJ, Schoonheim MM, et al
    Adipokines in multiple sclerosis patients are related to clinical and radiological measures.
    J Neurol. 2022 Dec 23. doi: 10.1007/s00415-022-11519.
    >> Share

  203. SEN MK, Hossain MJ, Mahns DA, Brew BJ, et al
    Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis.
    J Neurol. 2022 Dec 15. doi: 10.1007/s00415-022-11507.
    >> Share

  204. ALBERGONI M, Storelli L, Preziosa P, Rocca MA, et al
    The insula modulates the effects of aerobic training on cardiovascular function and ambulation in multiple sclerosis.
    J Neurol. 2022 Dec 12:1-10. doi: 10.1007/s00415-022-11513.
    >> Share

  205. GANZETTI M, Graves JS, Holm SP, Dondelinger F, et al
    Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.
    J Neurol. 2022 Dec 5. doi: 10.1007/s00415-022-11494.
    >> Share

  206. MOCCIA M, Affinito G, Berera G, Marrazzo G, et al
    Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
    J Neurol. 2022;269:6504-6511.
    >> Share

  207. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
    Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.
    J Neurol. 2022;269:6366-6376.
    >> Share

    November 2022
  208. SIMPSON R, Posa S, Bruno T, Simpson S, et al
    Conceptualization, use, and outcomes associated with compassion in the care of people with multiple sclerosis: a scoping review.
    J Neurol. 2022 Nov 29. doi: 10.1007/s00415-022-11497.
    >> Share

  209. PREZIOSA P, Rocca MA, Pagani E, Valsasina P, et al
    Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis.
    J Neurol. 2022 Nov 27. doi: 10.1007/s00415-022-11486.
    >> Share

  210. FILIPPI M, Preziosa P, Arnold DL, Barkhof F, et al
    Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.
    J Neurol. 2022 Nov 24. doi: 10.1007/s00415-022-11488.
    >> Share

  211. MIRMOSAYYEB O, Zivadinov R, Weinstock-Guttman B, Benedict RHB, et al
    Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11449.
    >> Share

  212. KWON YN, Woodhall M, Sung JJ, Kim KK, et al
    Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis.
    J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11458.
    >> Share

  213. KIM S, Kim KH, Chung HY, Park HJ, et al
    Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis.
    J Neurol. 2022 Nov 16. pii: 10.1007/s00415-022-11485.
    >> Share

  214. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
    Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
    J Neurol. 2022 Nov 14. pii: 10.1007/s00415-022-11405.
    >> Share

  215. GALPERIN I, Mirelman A, Schmitz-Hubsch T, Hsieh KL, et al
    Treadmill training with virtual reality to enhance gait and cognitive function among people with multiple sclerosis: a randomized controlled trial.
    J Neurol. 2022 Nov 11. pii: 10.1007/s00415-022-11469.
    >> Share

  216. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
    Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11479.
    >> Share

  217. SIMPSON R, Posa S, Langer L, Bruno T, et al
    A systematic review and meta-analysis exploring the efficacy of mindfulness-based interventions on quality of life in people with multiple sclerosis.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11451.
    >> Share

  218. TERESHKO Y, Gigli GL, Pez S, De Pellegrin A, et al
    New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11472.
    >> Share

  219. NIINO M, Fukumoto S, Okuno T, Sanjo N, et al
    Health-related quality of life in Japanese patients with multiple sclerosis.
    J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11453.
    >> Share

  220. KURI A, Vickaryous N, Awad A, Jacobs BM, et al
    Vitamin D genetic risk scores in multiple sclerosis.
    J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11466.
    >> Share

  221. JARIUS S, Haas J, Wildemann B
    Rho GTPase-activating protein 17 (ARHGAP17) as additional autoimmune target in ARHGAP26-IgG/anti-Ca autoantibody-associated autoimmune encephalitis.
    J Neurol. 2022 Nov 4. pii: 10.1007/s00415-022-11417.
    >> Share

  222. STRANO CMM, Sorrenti B, Bosco L, Falzone YM, et al
    Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report.
    J Neurol. 2022;269:6152-6154.
    >> Share

    October 2022
  223. OMARY R, Bockisch CJ, De Vere-Tyndall A, Pazahr S, et al
    Lesion follows function: video-oculography compared with MRI to diagnose internuclear ophthalmoplegia in patients with multiple sclerosis.
    J Neurol. 2022 Oct 31. pii: 10.1007/s00415-022-11428.
    >> Share

  224. WUSCHEK A, Bussas M, El Husseini M, Harabacz L, et al
    Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis.
    J Neurol. 2022 Oct 7. pii: 10.1007/s00415-022-11407.
    >> Share

  225. PREZIOSA P, Pagani E, Meani A, Marchesi O, et al
    NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis.
    J Neurol. 2022 Oct 6. pii: 10.1007/s00415-022-11415.
    >> Share

  226. COSTELLO F, Burton JM
    Contemporary management challenges in seropositive NMOSD.
    J Neurol. 2022;269:5674-5681.
    >> Share

  227. KANG L, Wan C
    Paraneoplastic syndrome in neuroophthalmology.
    J Neurol. 2022;269:5272-5282.
    >> Share

  228. LEVI-STRAUSS J, Provost C, Wane N, Jacquemont T, et al
    NMOSD typical brain lesions after COVID-19 mRNA vaccination.
    J Neurol. 2022;269:5213-5215.
    >> Share

  229. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
    J Neurol. 2022;269:5319-5327.
    >> Share

    September 2022
  230. ZHANG S, Yang S, Lu J, Liu S, et al
    CIDP-like autoimmune nodopathy complicated with focal segmental glomerulosclerosis: a case study and literature review.
    J Neurol. 2022 Sep 30. pii: 10.1007/s00415-022-11369.
    >> Share

  231. STASCHEIT F, Grittner U, Hoffmann S, Mergenthaler P, et al
    Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.
    J Neurol. 2022 Sep 27. pii: 10.1007/s00415-022-11389.
    >> Share

  232. MARGONI M, Pagani E, Preziosa P, Palombo M, et al
    In vivo quantification of brain soma and neurite density abnormalities in multiple sclerosis.
    J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11386.
    >> Share

  233. PAGANI E, Storelli L, Pantano P, Petsas N, et al
    Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis.
    J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11387.
    >> Share

  234. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 Sep 22. pii: 10.1007/s00415-022-11385.
    >> Share

  235. FILSER M, Buchner A, Fink GR, Gold SM, et al
    The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.
    J Neurol. 2022 Sep 21. pii: 10.1007/s00415-022-11359.
    >> Share

  236. CHAPPUIS M, Rousseau C, Bajeux E, Wiertlewski S, et al
    Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
    J Neurol. 2022 Sep 16. pii: 10.1007/s00415-022-11341.
    >> Share

  237. REYES-VEGA MF, Soto-Cabezas MG, Soriano-Moreno AN, Valle-Campos A, et al
    Clinical features of Guillain-Barre syndrome and factors associated with mortality during the 2019 outbreak in Peru.
    J Neurol. 2022 Sep 13. pii: 10.1007/s00415-022-11331.
    >> Share

  238. NICOLAS P, Marion-Moffet H, Gossez M, Vukusic S, et al
    Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies.
    J Neurol. 2022 Sep 12. pii: 10.1007/s00415-022-11353.
    >> Share

  239. MAIER A, Kapfenberger R, Katona I, Weis J, et al
    Nonregional small fibre neuropathy in cases of autoimmune autonomic neuropathy.
    J Neurol. 2022 Sep 9. pii: 10.1007/s00415-022-11340.
    >> Share

  240. CAPASSO N, Palladino R, Cerbone V, Spiezia AL, et al
    Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
    J Neurol. 2022 Sep 1. pii: 10.1007/s00415-022-11350.
    >> Share

    August 2022
  241. WOELFLE T, Pless S, Reyes O, Wiencierz A, et al
    Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
    J Neurol. 2022 Aug 30. pii: 10.1007/s00415-022-11306.
    >> Share

  242. GUEGUEN A, Hijazi B, Zuber K, Deschamps R, et al
    Generalization of ocular myasthenia gravis 10 years after onset.
    J Neurol. 2022 Aug 24. pii: 10.1007/s00415-022-11316.
    >> Share

  243. BARNAY M, Duval F, Sole G, Carla L, et al
    Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.
    J Neurol. 2022 Aug 22. pii: 10.1007/s00415-022-11345.
    >> Share

  244. LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
    Correction to: Burden of disease in myasthenia gravis: taking the patient's perspective.
    J Neurol. 2022 Aug 12. pii: 10.1007/s00415-022-11290.
    >> Share

  245. JAFARPOUR S, Banerjee A, Boyd NK, Vogel BN, et al
    Association of rare variants in genes of immune regulation with pediatric autoimmune CNS diseases.
    J Neurol. 2022 Aug 12. pii: 10.1007/s00415-022-11325.
    >> Share

  246. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study.
    J Neurol. 2022 Aug 8. pii: 10.1007/s00415-022-11295.
    >> Share

  247. KREFT KL, Robertson NP
    Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment.
    J Neurol. 2022 Aug 1. pii: 10.1007/s00415-022-11300.
    >> Share

    July 2022
  248. DORON A, Piura Y, Vigiser I, Kolb H, et al
    BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
    J Neurol. 2022 Jul 30. pii: 10.1007/s00415-022-11303.
    >> Share

  249. CAPUANO R, Altieri M, Conte M, Bisecco A, et al
    Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
    J Neurol. 2022 Jul 26. pii: 10.1007/s00415-022-11296.
    >> Share

  250. BLACKMAN G, Lim MF, Pollak T, Al-Diwani A, et al
    The clinical relevance of serum versus CSF NMDAR autoantibodies associated exclusively with psychiatric features: a systematic review and meta-analysis of individual patient data.
    J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11224.
    >> Share

  251. MUNOZ-JURADO A, Escribano BM, Aguera E, Caballero-Villarraso J, et al
    SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.
    J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11237.
    >> Share

  252. TAN X, Liu Y, Wu X, Guo Y, et al
    Guillain-Barre-like syndrome: an uncommon feature of CASPR2 and LGI1 autoimmunity.
    J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11248.
    >> Share

  253. EID K, Torkildsen O, Aarseth J, Celius EG, et al
    Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy.
    J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11249.
    >> Share

  254. MERGENTHALER P, Stetefeld HR, Dohmen C, Kohler S, et al
    Seronegative myasthenic crisis: a multicenter analysis.
    J Neurol. 2022;269:3904-3911.
    >> Share

  255. ALCALA C, Cubas L, Carratala S, Gascon F, et al
    NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
    J Neurol. 2022;269:3495-3500.
    >> Share

    June 2022
  256. CANNIZZARO M, Ferre L, Clarelli F, Giordano A, et al
    Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
    J Neurol. 2022 Jun 27. pii: 10.1007/s00415-022-11227.
    >> Share

  257. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    Correction to: A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 Jun 25. pii: 10.1007/s00415-022-11216.
    >> Share

  258. LEGUY S, Lefort M, Lescot L, Michaud A, et al
    COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients.
    J Neurol. 2022 Jun 23. pii: 10.1007/s00415-022-11215.
    >> Share

  259. SANDROFF BM, Motl RW, Roman CAF, Wylie GR, et al
    Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis.
    J Neurol. 2022 Jun 19. pii: 10.1007/s00415-022-11205.
    >> Share

  260. DORCET G, Migne H, Biotti D, Bost C, et al
    Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.
    J Neurol. 2022 Jun 2. pii: 10.1007/s00415-022-11197.
    >> Share

  261. ARINO H, Heartshorne R, Michael BD, Nicholson TR, et al
    Neuroimmune disorders in COVID-19.
    J Neurol. 2022;269:2827-2839.
    >> Share

  262. YOGANATHAN K, Stevenson A, Tahir A, Sadler R, et al
    Bedside and laboratory diagnostic testing in myasthenia.
    J Neurol. 2022;269:3372-3384.
    >> Share

  263. LAMBERT N, Lutteri L, Tshibanda L, Bianchi E, et al
    Anti-SOX1 antibody-associated acute hemorrhagic leukoencephalitis.
    J Neurol. 2022;269:3359-3362.
    >> Share

  264. JENTZER A, Carra-Dalliere C, Lozano C, Riviere S, et al
    Neuromyelitis optica spectrum disorder following COVID-19 infection with increase in pre-existing anti-aquaporin-4 antibodies.
    J Neurol. 2022;269:2850-2853.
    >> Share

  265. AYVACIOGLU CAGAN C, Temucin CM, Arslan D, Gocmen R, et al
    Isolated spinal cord granulomatous angiitis: a case report and review of the literature.
    J Neurol. 2022;269:3175-3179.
    >> Share

  266. VAN ROSMALEN MHJ, Froeling M, Mandija S, Hendrikse J, et al
    MRI of the intraspinal nerve roots in patients with chronic inflammatory neuropathies: abnormalities correlate with clinical phenotypes.
    J Neurol. 2022;269:3159-3166.
    >> Share

  267. ZIEMSSEN T, Lang M, Schmidt S, Albrecht H, et al
    Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    J Neurol. 2022;269:3276-3285.
    >> Share

  268. AKAISHI T, Misu T, Fujihara K, Takahashi T, et al
    Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
    J Neurol. 2022;269:3136-3146.
    >> Share

  269. DI SABATINO E, Gaetani L, Sperandei S, Fiacca A, et al
    The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
    J Neurol. 2022;269:3129-3135.
    >> Share

  270. MISCIOSCIA A, Puthenparampil M, Miante S, Pengo M, et al
    Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.
    J Neurol. 2022 Jun 1. pii: 10.1007/s00415-022-11183.
    >> Share

    May 2022
  271. HRASTELJ J, Robertson NP
    A role for the Epstein-Barr virus in multiple sclerosis aetiology?
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11177.
    >> Share

  272. GOLD R, Piani-Meier D, Kappos L, Bar-Or A, et al
    Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11166.
    >> Share

  273. JARIUS S, Komorowski L, Regula JU, Haas J, et al
    Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis.
    J Neurol. 2022 May 27. pii: 10.1007/s00415-022-11178.
    >> Share

  274. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11158.
    >> Share

  275. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Early use of high-efficacy diseasemodifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11193.
    >> Share

  276. BATTAGLIA MA, Bezzini D, Cecchini I, Cordioli C, et al
    Patients with multiple sclerosis: a burden and cost of illness study.
    J Neurol. 2022 May 23. pii: 10.1007/s00415-022-11169.
    >> Share

  277. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 May 12. pii: 10.1007/s00415-022-11109.
    >> Share

  278. HONE L, Jacobs BM, Marshall C, Giovannoni G, et al
    Age-specific effects of childhood body mass index on multiple sclerosis risk.
    J Neurol. 2022 May 9. pii: 10.1007/s00415-022-11161.
    >> Share

  279. SPARASCI D, Gobbi C, Castelnovo A, Riccitelli GC, et al
    Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping.
    J Neurol. 2022 May 4. pii: 10.1007/s00415-022-11143.
    >> Share

  280. GIANNOCCARO MP, Vacchiano V, Leone M, Camilli F, et al
    Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
    J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11142.
    >> Share

  281. SANSONE G, Bonifati DM
    Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
    J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11140.
    >> Share

  282. KIM H, Fraser S
    Neural correlates of dual-task walking in people with central neurological disorders: a systematic review.
    J Neurol. 2022;269:2378-2402.
    >> Share

  283. GELIBTER S, Bellavia G, Arbasino C, Arno N, et al
    Encephalopathy as a prognostic factor in adults with acute disseminated encephalomyelitis following COVID-19.
    J Neurol. 2022;269:2293-2300.
    >> Share

  284. WEISS D, Cantre D, Zettl UK, Storch A, et al
    Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab.
    J Neurol. 2022;269:2778-2780.
    >> Share

  285. HIROSE S, Hara M, Kamei S, Dalmau J, et al
    Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis.
    J Neurol. 2022;269:2486-2492.
    >> Share

    April 2022
  286. HVID LG, Stenager E, Dalgas U
    Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.
    J Neurol. 2022 Apr 28. pii: 10.1007/s00415-022-11134.
    >> Share

  287. EINSIEDLER M, Kremer L, Fleury M, Collongues N, et al
    Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.
    J Neurol. 2022 Apr 17. pii: 10.1007/s00415-022-11124.
    >> Share

  288. DUBBIOSO R, Bove M, Boccia D, D'Ambrosio V, et al
    Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis.
    J Neurol. 2022 Apr 13. pii: 10.1007/s00415-022-11114.
    >> Share

  289. ZHANG Y, Yin H, Zhang D, Xu Y, et al
    Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11118.
    >> Share

  290. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11063.
    >> Share

  291. STORELLI L, Pagani E, Meani A, Preziosa P, et al
    Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis.
    J Neurol. 2022 Apr 10. pii: 10.1007/s00415-022-11104.
    >> Share

  292. CAROLUS K, Fuchs TA, Bergsland N, Ramasamy D, et al
    Time course of lesion-induced atrophy in multiple sclerosis.
    J Neurol. 2022 Apr 8. pii: 10.1007/s00415-022-11094.
    >> Share

  293. MOOG TM, McCreary M, Wilson A, Stanley T, et al
    Direction and magnitude of displacement differ between slowly expanding and non-expanding multiple sclerosis lesions as compared to small vessel disease.
    J Neurol. 2022 Apr 5. pii: 10.1007/s00415-022-11089.
    >> Share

  294. BUONOMO AR, Viceconte G, Calabrese M, De Luca G, et al
    Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Apr 4. pii: 10.1007/s00415-022-11066.
    >> Share

  295. VANDEBERGH M, Degryse N, Dubois B, Goris A, et al
    Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.
    J Neurol. 2022 Apr 2. pii: 10.1007/s00415-022-11072.
    >> Share

  296. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.
    J Neurol. 2022;269:1758-1763.
    >> Share

  297. ROJAS JI, Pappolla A, Blaya P, Marrodan M, et al
    Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM.
    J Neurol. 2022;269:2073-2079.
    >> Share

  298. ABBOUD H, Salazar-Camelo A, George N, Planchon SM, et al
    Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.
    J Neurol. 2022;269:1786-1801.
    >> Share

  299. MASUDA H, Mori M, Yokouchi H, Uzawa A, et al
    Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders.
    J Neurol. 2022;269:1996-2003.
    >> Share

    March 2022
  300. DEANA C, Bagatto D, Battezzi A, Pecori D, et al
    Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
    J Neurol. 2022 Mar 30. pii: 10.1007/s00415-022-11097.
    >> Share

  301. BISECCO A, Fornasiero A, Bianco A, Cortese A, et al
    Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2022 Mar 27. pii: 10.1007/s00415-022-11083.
    >> Share

  302. WENZEL N, Wittayer M, Weber CE, Schirmer L, et al
    MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.
    J Neurol. 2022 Mar 25. pii: 10.1007/s00415-022-11082.
    >> Share

  303. ALLMAN M, Tallantyre E, Robertson NP
    Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies.
    J Neurol. 2022 Mar 14. pii: 10.1007/s00415-022-11053.
    >> Share

  304. MISTRI D, Cacciaguerra L, Storelli L, Meani A, et al
    The association between cognition and motor performance is beyond structural damage in relapsing-remitting multiple sclerosis.
    J Neurol. 2022 Mar 12. pii: 10.1007/s00415-022-11044.
    >> Share

  305. DU Y, Li C, Hao YF, Zhao C, et al
    Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11048.
    >> Share

  306. MARIOTTINI A, Bertozzi A, Marchi L, Di Cristinzi M, et al
    Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11003.
    >> Share

  307. ACHIRON A, Mandel M, Gurevich M, Dreyer-Alster S, et al
    Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    J Neurol. 2022 Mar 2. pii: 10.1007/s00415-022-11030.
    >> Share

  308. KUBICKI K, Grzybowski A
    Pioneers in neurology: Charles Miller Fisher (1913-2012).
    J Neurol. 2022;269:1727-1729.
    >> Share

  309. KANINIA S, Edey AJ, Maskell NA, Rice CM, et al
    Natalizumab-induced pneumonitis.
    J Neurol. 2022;269:1688-1690.
    >> Share

  310. KHAN E, Shrestha AK, Colantonio MA, Liberio RN, et al
    Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature.
    J Neurol. 2022;269:1121-1132.
    >> Share

  311. WANG Y, Wang Y, Huo L, Li Q, et al
    SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature.
    J Neurol. 2022;269:1071-1092.
    >> Share

  312. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.
    J Neurol. 2022;269:1663-1669.
    >> Share

  313. XIE H, Shao Y, Du J, Song Y, et al
    Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
    J Neurol. 2022;269:1641-1650.
    >> Share

  314. NISSEN MS, Orvik MS, Nilsson AC, Ryding M, et al
    NMDA-receptor encephalitis in Denmark from 2009 to 2019: a national cohort study.
    J Neurol. 2022;269:1618-1630.
    >> Share

  315. CACCIAGUERRA L, Storelli L, Radaelli M, Mesaros S, et al
    Application of deep-learning to the seronegative side of the NMO spectrum.
    J Neurol. 2022;269:1546-1556.
    >> Share

  316. HU J, Sun C, Lu J, Zhao C, et al
    Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
    J Neurol. 2022;269:1250-1263.
    >> Share

  317. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
    J Neurol. 2022 Mar 1. pii: 10.1007/s00415-022-11021.
    >> Share

    February 2022
  318. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Feb 22. pii: 10.1007/s00415-022-11019.
    >> Share

  319. BERG-HANSEN P, Moen SM, Austeng A, Gonzales V, et al
    Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation.
    J Neurol. 2022 Feb 15. pii: 10.1007/s00415-022-10998.
    >> Share

  320. RICCARDO BA, Giulio V, Massimiliano C, Giovanna L, et al
    Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Feb 14. pii: 10.1007/s00415-022-11009.
    >> Share

  321. CHIARAVALLOTI ND, Costa SL, Moore NB, Costanza K, et al
    The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial.
    J Neurol. 2022 Feb 12. pii: 10.1007/s00415-022-10980.
    >> Share

  322. SOULAGES A, Sibon I, Vallat JM, Ellie E, et al
    Neurologic manifestations of giant cell arteritis.
    J Neurol. 2022 Feb 6. pii: 10.1007/s00415-022-10991.
    >> Share

  323. ALCALA C, Quintanilla-Bordas C, Gascon F, Sempere AP, et al
    Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
    J Neurol. 2022 Feb 2. pii: 10.1007/s00415-022-10989.
    >> Share

  324. ISMAIL II, Salama S
    Association of CNS demyelination and COVID-19 infection: an updated systematic review.
    J Neurol. 2022;269:541-576.
    >> Share

  325. PATZIG M, Forbrig R, Kupper C, Eren O, et al
    Diagnosis and follow-up evaluation of central nervous system vasculitis: an evaluation of vessel-wall MRI findings.
    J Neurol. 2022;269:982-996.
    >> Share

  326. BUKHARI W, Khalilidehkordi E, Mason DF, Barnett MH, et al
    NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand.
    J Neurol. 2022;269:836-845.
    >> Share

  327. SPINA E, Doneddu PE, Liberatore G, Cocito D, et al
    Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP.
    J Neurol. 2022;269:907-912.
    >> Share

  328. BUS SRM, Broers MC, Lucke IM, Bunschoten C, et al
    Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.
    J Neurol. 2022;269:945-955.
    >> Share

  329. LANDI D, Signori A, Cellerino M, Fenu G, et al
    What happens after fingolimod discontinuation? A multicentre real-life experience.
    J Neurol. 2022;269:796-804.
    >> Share

    January 2022
  330. VIRGILIO E, Vecchio D, Crespi I, Puricelli C, et al
    Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.
    J Neurol. 2022 Jan 28. pii: 10.1007/s00415-021-10945.
    >> Share

  331. PROSCHINGER S, Kuhwand P, Rademacher A, Walzik D, et al
    Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression.
    J Neurol. 2022 Jan 27. pii: 10.1007/s00415-021-10935.
    >> Share

  332. GADOTH A, Segal Y, Paran Y, Aizenstein O, et al
    The importance of tissue-based assay in the diagnosis of autoimmune encephalitis.
    J Neurol. 2022 Jan 25. pii: 10.1007/s00415-022-10973.
    >> Share

  333. PAPADOPOULOS D, Gklinos P, Psarros G, Drellia K, et al
    Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.
    J Neurol. 2022 Jan 23. pii: 10.1007/s00415-021-10932.
    >> Share

  334. BERGAMASCHI R, Mallucci G, Fusco S, Montomoli C, et al
    Disability and mortality in a cohort of MS patients: how the real-world scenario is changed.
    J Neurol. 2022 Jan 14. pii: 10.1007/s00415-021-10940.
    >> Share

  335. MORANO A, Cerulli Irelli E, Fanella M, Orlando B, et al
    Olfactory impairment in autoimmune encephalitis: another piece of the puzzle.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-022-10959.
    >> Share

  336. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-021-10958.
    >> Share

  337. CRUZ RA, Varkey T, Flavia A, Samways APA, et al
    Hearing abnormalities in multiple sclerosis: clinical semiology and pathophysiologic mechanisms.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10915.
    >> Share

  338. KORSEN M, Pfeuffer S, Rolfes L, Meuth SG, et al
    Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10956.
    >> Share

  339. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10951.
    >> Share

  340. BIGAUT K, Kremer L, Fabacher T, Ahle G, et al
    Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10950.
    >> Share

  341. THOMAS R, Wynford-Thomas R, Robertson NP
    Advances in the use of stem cell transplants in the treatment of multiple sclerosis.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10927.
    >> Share

  342. TALAEI M, Robertson NP
    Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy.
    J Neurol. 2022;269:534-536.
    >> Share

  343. ZRZAVY T, Wielandner A, Haider L, Bartsch S, et al
    FLAIR(2) post-processing: improving MS lesion detection in standard MS imaging protocols.
    J Neurol. 2022;269:461-467.
    >> Share

  344. XU J, Guo Y, Li J, Lv X, et al
    Progressive cortical and sub-cortical alterations in patients with anti-N-methyl-D-aspartate receptor encephalitis.
    J Neurol. 2022;269:389-398.
    >> Share

  345. HELMCHEN C, Buttler GM, Markewitz R, Hummel K, et al
    Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2.
    J Neurol. 2022;269:49-54.
    >> Share

  346. DE LOTT LB, Bennett JL, Costello F
    The changing landscape of optic neuritis: a narrative review.
    J Neurol. 2022;269:111-124.
    >> Share

    December 2021
  347. LEGUY S, Le Page E, Drapier S
    Elderly onset neuromyelitis optica spectrum disorder: a case report.
    J Neurol. 2021;268:4897-4898.
    >> Share

  348. SRIWASTAVA S, Tandon M, Podury S, Prasad A, et al
    COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2.
    J Neurol. 2021;268:4448-4478.
    >> Share

  349. KONIG N, Stetefeld HR, Dohmen C, Mergenthaler P, et al
    MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation.
    J Neurol. 2021;268:4824-4833.
    >> Share

  350. FLANAGAN EP
    Paraneoplastic disorders of the nervous system.
    J Neurol. 2021;268:4899-4907.
    >> Share

  351. CABAL-HERRERA AM, Mateen FJ
    COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica.
    J Neurol. 2021;268:4479-4482.
    >> Share

  352. SIRITHO S, Nopsopon T, Pongpirul K
    Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis.
    J Neurol. 2021;268:4549-4562.
    >> Share

  353. HOLMOY T, Hoglund RA, Illes Z, Myhr KM, et al
    Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
    J Neurol. 2021;268:4522-4536.
    >> Share

    November 2021
  354. KAMBADJA B, Marion H, Cousyn L, Mezouar N, et al
    When should we test patients with epilepsy for autoimmune antibodies? Results from a French retrospective single center study.
    J Neurol. 2021 Nov 23. pii: 10.1007/s00415-021-10894.
    >> Share

  355. ANDERSEN LK, Jakobsson AS, Revsbech KL, Vissing J, et al
    Causes of symptom dissatisfaction in patients with generalized myasthenia gravis.
    J Neurol. 2021 Nov 21. pii: 10.1007/s00415-021-10902.
    >> Share

  356. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10906.
    >> Share

  357. LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
    Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10893.
    >> Share

  358. SRIWASTAVA S, Chaudhary D, Srivastava S, Beard K, et al
    Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10910.
    >> Share

  359. LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
    Burden of disease in myasthenia gravis: taking the patient's perspective.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10891.
    >> Share

  360. CHAMBERLAIN JL, Huda S, Whittam DH, Matiello M, et al
    Correction to: Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
    J Neurol. 2021 Nov 15. pii: 10.1007/s00415-021-10896.
    >> Share

  361. MCHATTIE AW, Coebergh J, Khan F, Morgante F, et al
    Palilalia as a prominent feature of anti-NMDA receptor encephalitis in a woman with COVID-19.
    J Neurol. 2021;268:3995-3997.
    >> Share

    October 2021
  362. FUCHS TA, Schoonheim MM, Broeders TAA, Hulst HE, et al
    Functional network dynamics and decreased conscientiousness in multiple sclerosis.
    J Neurol. 2021 Oct 29. pii: 10.1007/s00415-021-10860.
    >> Share

  363. WASHINGTON F, Langdon D
    Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.
    J Neurol. 2021 Oct 21. pii: 10.1007/s00415-021-10850.
    >> Share

  364. ALSCHULER KN, Whibley D, Kratz AL, Jensen MP, et al
    Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome.
    J Neurol. 2021 Oct 19. pii: 10.1007/s00415-021-10842.
    >> Share

  365. BURT RK, Han X, Quigley K, Helenowski IB, et al
    Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
    J Neurol. 2021 Oct 11. pii: 10.1007/s00415-021-10820.
    >> Share

  366. FILIPPI M, Danesi R, Derfuss T, Duddy M, et al
    Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
    J Neurol. 2021 Oct 9. pii: 10.1007/s00415-021-10836.
    >> Share

  367. PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
    Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
    J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
    >> Share

  368. AL-ANSARI A, Robertson NP
    Autoimmune encephalitis: clinical presentation, investigation and treatment.
    J Neurol. 2021;268:3935-3937.
    >> Share

  369. FUKAMI Y, Iijima M, Koike H, Yamada S, et al
    Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients.
    J Neurol. 2021;268:3835-3844.
    >> Share

  370. JARIUS S, Wilken D, Haas J, Ruprecht K, et al
    Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction.
    J Neurol. 2021;268:3758-3765.
    >> Share

  371. QUEROL L, Crabtree M, Herepath M, Priedane E, et al
    Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).
    J Neurol. 2021;268:3706-3716.
    >> Share

  372. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Oct 1. pii: 10.1007/s00415-021-10823.
    >> Share

    September 2021
  373. AHMED A, Kok ZQ, Coles A, Scoffings DJ, et al
    Susac's syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution.
    J Neurol. 2021 Sep 29. pii: 10.1007/s00415-021-10802.
    >> Share

  374. PUTHENPARAMPIL M, Perini P, Bergamaschi R, Capobianco M, et al
    Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors.
    J Neurol. 2021 Sep 27. pii: 10.1007/s00415-021-10782.
    >> Share

  375. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
    J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
    >> Share

  376. BOZOVIC I, Ilic Zivojinovic J, Peric S, Kostic M, et al
    Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.
    J Neurol. 2021 Sep 4. pii: 10.1007/s00415-021-10759.
    >> Share

  377. BERCIANO J
    Pathogenic events in very early Guillain-Barre syndrome: neither demyelination nor axonal degeneration but endoneurial inflammatory oedema.
    J Neurol. 2021 Sep 3. pii: 10.1007/s00415-021-10773.
    >> Share

  378. ANDERSEN MA, Buron MD, Magyari M
    Late-onset MS is associated with an increased rate of reaching disability milestones.
    J Neurol. 2021;268:3352-3360.
    >> Share

  379. HOFSTADT-VAN OY U, Stankovic S, Kelbel C, Oswald D, et al
    Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.
    J Neurol. 2021;268:3125-3128.
    >> Share

  380. VAN LOOY E, Veenker L, Steyaert A, Leenders J, et al
    COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:3129-3131.
    >> Share

    August 2021
  381. SUN J, Xie Y, Wang Q, Shen J, et al
    Genes associated with grey matter volume reduction in multiple sclerosis.
    J Neurol. 2021 Aug 29. pii: 10.1007/s00415-021-10777.
    >> Share

  382. BLOCK VJ, Pitsch EA, Gopal A, Zhao C, et al
    Identifying falls remotely in people with multiple sclerosis.
    J Neurol. 2021 Aug 17. pii: 10.1007/s00415-021-10743.
    >> Share

  383. MARGONI M, Preziosa P, Filippi M, Rocca MA, et al
    Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
    J Neurol. 2021 Aug 11. pii: 10.1007/s00415-021-10744.
    >> Share

  384. ALVINO B, Arianna F, Assunta B, Antonio C, et al
    Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2021 Aug 4. pii: 10.1007/s00415-021-10737.
    >> Share

  385. PARDO G, Coates S, Okuda DT
    Outcome measures assisting treatment optimization in multiple sclerosis.
    J Neurol. 2021 Aug 2. pii: 10.1007/s00415-021-10674.
    >> Share

  386. FIONDA L, Di Pasquale A, Morino S, Leonardi L, et al
    Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up.
    J Neurol. 2021;268:3011-3019.
    >> Share

  387. CORTESE R, Prosperini L, Stasolla A, Haggiag S, et al
    Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
    J Neurol. 2021;268:2895-2899.
    >> Share

  388. CILINGIR V, Batur M
    First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions.
    J Neurol. 2021;268:2858-2865.
    >> Share

  389. WANSCHITZ JV, Kaml M, Pfausler B, Helbok R, et al
    Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up.
    J Neurol. 2021;268:2700-2702.
    >> Share

    July 2021
  390. O SULLIVAN C, Zach F, Moser T, Pilz G, et al
    Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.
    J Neurol. 2021 Jul 24. pii: 10.1007/s00415-021-10707.
    >> Share

  391. FERRARO D, Iaffaldano P, Guerra T, Inglese M, et al
    Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    J Neurol. 2021 Jul 22. pii: 10.1007/s00415-021-10708.
    >> Share

  392. RAUMA I, Mustonen T, Seppa JM, Ukkonen M, et al
    Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
    J Neurol. 2021 Jul 13. pii: 10.1007/s00415-021-10664.
    >> Share

  393. NIESSEN A, Schwarz B, Urban M, Kramer S, et al
    Aseptic meningitis after glatiramer acetate.
    J Neurol. 2021;268:2589-2590.
    >> Share

  394. STARMANS NLP, van Dijk MR, Kappelle LJ, Frijns CJM, et al
    Sneddon syndrome: a comprehensive clinical review of 53 patients.
    J Neurol. 2021;268:2450-2457.
    >> Share

  395. MASUCCIO FG, Barra M, Claudio G, Claudio S, et al
    A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection.
    J Neurol. 2021;268:2327-2330.
    >> Share

    June 2021
  396. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
    PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
    >> Share

  397. SANKARI SE, Van Essche C, van Pesch V
    Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.
    >> Share

  398. KOGEL AK, Gold R, Schneider R
    CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.
    >> Share

  399. S G, S L, C Z, A N, et al
    Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
    >> Share

  400. HANNINEN K, Viitala M, Atula S, Laakso SM, et al
    Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
    J Neurol. 2021 Jun 25. pii: 10.1007/s00415-021-10673.
    >> Share

  401. HAVLA J, Schultz Y, Zimmermann H, Hohlfeld R, et al
    First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neurol. 2021 Jun 11. pii: 10.1007/s00415-021-10648.
    >> Share

  402. KIM SH, Baek SH, Lee SU, Yu S, et al
    Optic disc edema as a sole manifestation of anti-GQ1b antibody syndrome.
    J Neurol. 2021;268:2263-2266.
    >> Share

  403. DAO LM, Machule ML, Bacher P, Hoffmann J, et al
    Decreased inflammatory cytokine production of antigen-specific CD4(+) T cells in NMDA receptor encephalitis.
    J Neurol. 2021;268:2123-2131.
    >> Share

  404. LLORENTE AYUSO L, Torres Rubio P, Beijinho do Rosario RF, Giganto Arroyo ML, et al
    Bickerstaff encephalitis after COVID-19.
    J Neurol. 2021;268:2035-2037.
    >> Share

    May 2021
  405. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
    Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
    J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
    >> Share

  406. CHEN MH, Chiaravalloti ND, DeLuca J
    Neurological update: cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
    >> Share

  407. HOU Y, Shao K, Yan Y, Dai T, et al
    Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy.
    J Neurol. 2021 May 21. pii: 10.1007/s00415-021-10621.
    >> Share

  408. KILIC MA, Yoruk Yildirim ZN, Oner A, Yesil E, et al
    Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19: Morvan syndrome.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10614.
    >> Share

  409. ZRZAVY T, Pfitzner A, Flachenecker P, Rommer P, et al
    Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10596.
    >> Share

  410. HILDESHEIM FE, Benedict RHB, Zivadinov R, Dwyer MG, et al
    Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.
    J Neurol. 2021 May 16. pii: 10.1007/s00415-021-10594.
    >> Share

  411. TOMMASIN S, Cocozza S, Taloni A, Gianni C, et al
    Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis.
    J Neurol. 2021 May 10. pii: 10.1007/s00415-021-10605.
    >> Share

  412. RUGGIERI S, Petracca M, De Giglio L, De Luca F, et al
    A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.
    J Neurol. 2021 May 3. pii: 10.1007/s00415-021-10576.
    >> Share

  413. THOUIN A, Gastaldi M, Woodhall M, Jacobson L, et al
    Comparison of N-methyl-D-aspartate receptor antibody assays using live or fixed substrates.
    J Neurol. 2021;268:1818-1826.
    >> Share

    April 2021
  414. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2021 Apr 22. pii: 10.1007/s00415-021-10559.
    >> Share

  415. COVEY TJ, Golan D, Doniger GM, Sergott R, et al
    Visual evoked potential latency predicts cognitive function in people with multiple sclerosis.
    J Neurol. 2021 Apr 18. pii: 10.1007/s00415-021-10561.
    >> Share

  416. CENTONZE D, Rocca MA, Gasperini C, Kappos L, et al
    Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
    J Neurol. 2021 Apr 12. pii: 10.1007/s00415-021-10545.
    >> Share

  417. WILF-YARKONI A, Lotan I, Steiner I, Hellmann MA, et al
    Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10544.
    >> Share

  418. NYGAARD MKE, Langeskov-Christensen M, Dalgas U, Eskildsen SF, et al
    Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10543.
    >> Share

  419. URBAIN F, Puyade M, Labeyrie C, Maubeuge N, et al
    Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation.
    J Neurol. 2021;268:1536-1539.
    >> Share

  420. KAPOOR M, Keh R, Compton L, Morrow S, et al
    Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy.
    J Neurol. 2021;268:1485-1490.
    >> Share

  421. NETRAVATHI M, Holla VV, Nalini A, Yadav R, et al
    Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder.
    J Neurol. 2021;268:1419-1433.
    >> Share

  422. CHAUDHARY UJ, Rajabally YA
    Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:1366-1373.
    >> Share

    March 2021
  423. VAN ROSMALEN MHJ, Goedee HS, van der Gijp A, Witkamp TD, et al
    Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies.
    J Neurol. 2021;268:978-988.
    >> Share

  424. MATHIS S, Soulages A, Le Masson G, Vallat JM, et al
    Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes.
    J Neurol. 2021;268:879-890.
    >> Share

    February 2021
  425. YOO JS, Kim YS, Kim HY, Kwon HS, et al
    Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke.
    J Neurol. 2021 Feb 6. pii: 10.1007/s00415-021-10432.
    >> Share

  426. MARTIN T, Duke S, Kumar V, Fadhil A, et al
    NMDAR antibody encephalitis overlapping with CLIPPERS syndrome in a psoriasis patient on adalimumab.
    J Neurol. 2021;268:714-716.
    >> Share

  427. SCHROTER N, Weiller C, Rauer S, Waller CF, et al
    Anti-glycin-receptor antibody related stiff-person syndrome under treatment with an immune checkpoint inhibitor.
    J Neurol. 2021;268:709-711.
    >> Share

  428. OKADA K, Seki M, Yaguchi H, Sakuta K, et al
    Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature.
    J Neurol. 2021;268:680-688.
    >> Share

  429. BERGMAN J, Burman J, Bergenheim T, Svenningsson A, et al
    Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
    J Neurol. 2021;268:651-657.
    >> Share

    January 2021
  430. STOECKLEIN VM, Kellert L, Patzig M, Kupper C, et al
    Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety.
    J Neurol. 2021;268:367-376.
    >> Share

  431. KASS-ILIYYA L, Snowden JA, Thorpe A, Jessop H, et al
    Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience.
    J Neurol. 2021;268:265-275.
    >> Share

    July 2020
  432. BIEN CG, Bien CI, Dogan Onugoren M, De Simoni D, et al
    Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.
    J Neurol. 2020;267:2101-2114.
    >> Share

  433. MUNIZ-CASTRILLO S, Ambati A, Dubois V, Vogrig A, et al
    Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies.
    J Neurol. 2020;267:1906-1911.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016